Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians
Authors:
- Anthony M MarinakiAMAnthony M Marinaki
- Monica ArenasMAMonica Arenas
- Zubair H KhanZKZubair H Khan
- Cathryn M LewisCLCathryn M Lewis
- El-Monsor Shobowale-BakreESEl-Monsor Shobowale-Bakre
- Emilia EscuredoEEEmilia Escuredo
- Lynette D FairbanksLFLynette D Fairbanks
- John F MayberryJohn F Mayberry
- Antony C WicksAWAntony C Wicks
- Azhar AnsariAAAzhar Ansari
- Jeremy SandersonJSJeremy Sanderson
- John A DuleyJDJohn A Duley
- 1 February 2003
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 13 (2) , 97-105
Abstract
Polymorphisms in the TPMT gene open reading frame (ORF) are associated with reduced TPMT activity. Variable number tandem repeats (VNTR*3 to VNTR*9) in the promoter region of the gene consisting of combinations of Type A, B and C repeat units, may modulate TPMT activity. Here we present the allele frequencies of genetic modifiers of TPMT activity in a British Asian population, as well as the concordance between intermediate TPMT activity and ORF and VNTR genotypes in a predominantly Caucasian population. VNTR type and ORF mutations were determined in two selected TPMT activity ranges, intermediate activity (4–8 U, 108 patients), normal (12–15 U, 53 patients) and in 85 British Asians. In British Asians, TPMT*3C was the prevalent mutant allele (four heterozygotes). One patient was heterozygous for TPMT*3A. Overall VNTR frequencies did not differ from Caucasians. Three new VNTR alleles were designated VNTR*6c, VNTR*6d, and VNTR*7c. Forty-one percent of patients with intermediate activity were heterozygous for a TPMT ORF mutation (3A, 2B, 1C). Marked linkage disequilibrium was noted between VNTR*6b - TPMT*3A (D′ = 1), VNTR*4b - TPMT*3C (D′ = 0.67) and VNTR*6a - TPMT*1 (D′ = 1) alleles. As a result, significant differences (P< 0.05) in the distribution of Type A, B or the total number of repeats summed for both alleles, were found between the ORF heterozygous intermediate activity group and the wild-type intermediate or normal activity groups. No significant difference was found between the two wild-type groups. Our results suggest that TPMT gene VNTRs do not significantly modulate enzyme activity.Keywords
This publication has 39 references indexed in Scilit:
- Polymorphism of the thiopurine S-methyltransferase gene in African- AmericansHuman Molecular Genetics, 1999
- Clinical Implications of Thiopurine Methyltransferase-Optimization of Drug Dosage and Potential Drug InteractionsTherapeutic Drug Monitoring, 1998
- Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.Journal of Clinical Investigation, 1998
- Detection of known and new mutations in the thiopurineS-methyltransferase gene by single-strand conformation polymorphism analysisHuman Mutation, 1998
- Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*Clinical Pharmacology & Therapeutics, 1997
- Individualizing Therapy with 6-Mercaptopurine and 6-Thioguanine Related to the Thiopurine Methyltransferase Genetic PolymorphismTherapeutic Drug Monitoring, 1996
- A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.Proceedings of the National Academy of Sciences, 1995
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989
- Human kidney thiopurine methyltransferase purification and biochemical propertiesBiochemical Pharmacology, 1983
- Metabolism of Thiopyrimidines and ThiopurinesJournal of Biological Chemistry, 1963